Form 4: Sarepta Therapeutics Director M. Kathleen Behrens Reports Stock and Option Transactions

Director M. Kathleen Behrens reports acquisition of Sarepta Therapeutics stock and stock options.

Summary

• M. Kathleen Behrens, a director of Sarepta Therapeutics, reported transactions involving the company's securities.
• On March 1, 2024, Behrens acquired 1,846 shares of common stock through restricted stock units (RSUs) that will vest on March 1, 2025.
• On the same date, Behrens also acquired options to purchase 3,679 shares of common stock at an exercise price of $128.67, exercisable from March 1, 2025, to March 1, 2034.
• Behrens also indirectly owns 10,000 shares of common stock through a trust.
• Following these transactions, Behrens directly owns 176,839 shares of Sarepta Therapeutics common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitive.

Positives

• The acquisition of shares and options by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transactions could influence investor sentiment regarding Sarepta Therapeutics.

Key Dates